The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | Quality improvement initiative to optimize AE management for bispecifics for DLBCL in the community
In this video, Krish Patel, MD, Sarah Cannon Research Institute, Nashville, TN, discusses a quality improvement initiative that aimed to help community oncology sites to develop confidence in using bispecific antibodies for the treatment of diffuse large B-cell lymphoma (DLBCL) and to optimize processes for adverse event (AE) management in this setting. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
